As it focuses resources on Duchenne muscular dystrophy (DMD) clinical candidates and key preclinical programs, Entrada Therapeutics disclosed layoff and hiring plans in an April 29 SEC filing. Although the biotech will hire to support a planned global clinical trial for Duchenne, it will also reduce research staff, affecting about 20% of its workforce.
